Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00286481 · ClinicalTrials.gov registry record · Phase 3

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

A Phase 3 study, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
1,362
Enrollment target

NCT00286481 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,362 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00286481, a Phase 3 study, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
1,362 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with simvastatin on cholesterol levels in treating patients with elevated cholesterol.

Interventions

  • DRUG Simvastatin
  • DRUG Lapaquistat acetate and simvastatin

Trial Details

FieldValue
Enrollment Target 1,362 participants
Start Date 2006-03
Est. Completion 2007-05
Phase Phase 3

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT00286481

The ClinicalTrials.gov registry entry for NCT00286481 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Simvastatin is the first listed.

NCT00286481 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00286481 about?

NCT00286481 is a clinical study titled "Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia". The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with simvastatin on cholesterol levels in treating patients with elevated cholesterol.

What is the current status of trial NCT00286481?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,362 participants. The study started on 2006-03. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00286481?

The interventions under investigation include: Simvastatin (DRUG), Lapaquistat acetate and simvastatin (DRUG).

Who is sponsoring clinical trial NCT00286481?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.